These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7027749)

  • 1. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus.
    Madsbad S; Krarup T; McNair P; Christiansen C; Faber OK; Transbøl I; Binder C
    Acta Med Scand; 1981; 210(3):153-6. PubMed ID: 7027749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus.
    Faber OK; Binder C
    Diabetes; 1977 Jul; 26(7):605-10. PubMed ID: 326604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion.
    Hsieh SD; Iwamoto Y; Matsuda A; Kuzuya T
    Endocrinol Jpn; 1987 Aug; 34(4):561-7. PubMed ID: 3315640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of glucagon on islet beta cell function in patients with diabetes mellitus.
    Wang T; Xiao XH; Li WH; Wang H; Sun Q; Yuan T; Yang GH
    Chin Med Sci J; 2008 Jun; 23(2):117-20. PubMed ID: 18686632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon.
    Hendriksen C; Faber OK; Drejer J; Binder C
    Diabetologia; 1977 Dec; 13(6):615-9. PubMed ID: 338408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma C-peptide response to arginine in insulin-dependent diabetic subjects.
    Giugliano D; Luyckx AS; Lefebvre PJ
    J Endocrinol Invest; 1980; 3(1):19-23. PubMed ID: 6989887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basal and glucagon-stimulated plasma C-peptide concentrations in healthy dogs, dogs with diabetes mellitus, and dogs with hyperadrenocorticism.
    Montgomery TM; Nelson RW; Feldman EC; Robertson K; Polonsky KS
    J Vet Intern Med; 1996; 10(3):116-22. PubMed ID: 8743209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-C-peptide test as a measure of insulin requirement in type 2 diabetes: evaluation of stopping insulin therapy in eleven patients.
    Viikari J; Rönnemaa T; Koskinen P
    Ann Clin Res; 1987; 19(3):178-82. PubMed ID: 3314647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum C peptide and IRI levels after administration of glucagon and glucose in non-insulin-dependent diabetics.
    Jayyab AK; Heding LG; Czyzyk A; Malczewski B; Królewski AS
    Horm Metab Res; 1982 Mar; 14(3):112-6. PubMed ID: 7040196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-peptide measurement and its clinical usefulness: a review.
    Bonser AM; Garcia-Webb P
    Ann Clin Biochem; 1981 Jul; 18(Pt 4):200-6. PubMed ID: 7025733
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus.
    Gjessing HJ; Reinholdt B; Faber OK; Pedersen O
    Acta Endocrinol (Copenh); 1991 May; 124(5):556-62. PubMed ID: 2028714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproducibility of beta-cell function estimates in non-insulin-dependent diabetes mellitus.
    Gjessing HJ; Damsgaard EM; Matzen LE; Frøland A; Faber OK
    Diabetes Care; 1987; 10(5):558-62. PubMed ID: 3315512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.
    Nauck MA; Sauerwald A; Ritzel R; Holst JJ; Schmiegel W
    Diabetes Care; 1998 Nov; 21(11):1925-31. PubMed ID: 9802745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
    Ahrén B; Larsson H; Holst JJ
    J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproducibility of the glucagon test.
    Arnold-Larsen S; Madsbad S; Kühl C
    Diabet Med; 1987; 4(4):299-303. PubMed ID: 2956039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin on blood glucose, insulin and C-peptide responses to glucagon in non-insulin dependent diabetics.
    Ferlito S; Del Campo F; Di Vincenzo S; Damante G; Coco R; Branca S; Fichera C
    Farmaco Sci; 1983 Apr; 38(4):248-54. PubMed ID: 6345193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum C-peptide concentrations and their value in evaluating the usefulness of insulin therapy in elderly diabetics.
    Kyllästinen M; Elfving S
    Gerontology; 1986; 32(6):317-26. PubMed ID: 3556328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.
    Shapiro ET; Van Cauter E; Tillil H; Given BD; Hirsch L; Beebe C; Rubenstein AH; Polonsky KS
    J Clin Endocrinol Metab; 1989 Sep; 69(3):571-6. PubMed ID: 2503533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of fasting hyperglycemia and known non-insulin-dependent diabetes mellitus classified by plasma C-peptide: Fredericia survey of subjects 60-74 yr old.
    Damsgaard EM; Faber OK; Frøland A; Green A; Hauge M; Holm NV; Iversen S
    Diabetes Care; 1987; 10(1):26-32. PubMed ID: 3552511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.